NASDAQ:ENTA - Enanta Pharmaceuticals Stock Price, Price Target & More

$87.43 -1.91 (-2.14 %)
(As of 04/19/2018 08:07 AM ET)
Previous Close$89.34
Today's Range$85.44 - $89.76
52-Week Range$29.46 - $95.91
Volume231,900 shs
Average Volume210,369 shs
Market Capitalization$1.71 billion
P/E Ratio46.53
Dividend YieldN/A
Beta1.07

About Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals logoEnanta Pharmaceuticals, Inc., a biotechnology company, focuses on discovering and developing small molecule drugs for the treatment of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. It has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.

Receive ENTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ENTA
CUSIPN/A
Phone617-607-0800

Debt

Debt-to-Equity RatioN/A
Current Ratio12.88%
Quick Ratio12.88%

Price-To-Earnings

Trailing P/E Ratio46.53
Forward P/E Ratio84.07
P/E GrowthN/A

Sales & Book Value

Annual Sales$102.81 million
Price / Sales16.29
Cash Flow$1.0529 per share
Price / Cash83.04
Book Value$15.80 per share
Price / Book5.53

Profitability

EPS (Most Recent Fiscal Year)$0.91
Net Income$17.71 million
Net Margins26.35%
Return on Equity13.33%
Return on Assets12.50%

Miscellaneous

Employees89
Outstanding Shares19,160,000

How to Become a New Pot Stock Millionaire

Enanta Pharmaceuticals (NASDAQ:ENTA) Frequently Asked Questions

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals (NASDAQ:ENTA) posted its earnings results on Wednesday, February, 7th. The biotechnology company reported $0.78 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.05 by $0.73. The biotechnology company earned $38.11 million during the quarter, compared to the consensus estimate of $27.26 million. Enanta Pharmaceuticals had a net margin of 26.35% and a return on equity of 13.33%. View Enanta Pharmaceuticals' Earnings History.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Enanta Pharmaceuticals.

What price target have analysts set for ENTA?

4 equities research analysts have issued twelve-month price objectives for Enanta Pharmaceuticals' stock. Their predictions range from $36.00 to $80.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $51.75 in the next year. View Analyst Ratings for Enanta Pharmaceuticals.

Who are some of Enanta Pharmaceuticals' key competitors?

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the folowing people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 62)
  • Mr. Paul J. Mellett Jr., Sr. VP-Fin. & Admin., CFO and Principal Accounting Officer (Age 63)
  • Dr. Yat Sun Or, Sr. VP-R&D and Chief Scientific Officer (Age 66)
  • Dr. Nathalie Adda, Sr. VP & Chief Medical Officer (Age 52)
  • Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 64)

Has Enanta Pharmaceuticals been receiving favorable news coverage?

Headlines about ENTA stock have trended somewhat positive this week, Accern reports. The research firm identifies positive and negative media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Enanta Pharmaceuticals earned a coverage optimism score of 0.17 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 45.80 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $87.43.

How big of a company is Enanta Pharmaceuticals?

Enanta Pharmaceuticals has a market capitalization of $1.71 billion and generates $102.81 million in revenue each year. The biotechnology company earns $17.71 million in net income (profit) each year or $0.91 on an earnings per share basis. Enanta Pharmaceuticals employs 89 workers across the globe.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The biotechnology company can be reached via phone at 617-607-0800 or via email at [email protected]


MarketBeat Community Rating for Enanta Pharmaceuticals (ENTA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  165 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  351
MarketBeat's community ratings are surveys of what our community members think about Enanta Pharmaceuticals and other stocks. Vote "Outperform" if you believe ENTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENTA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Enanta Pharmaceuticals in the last 12 months. Their average twelve-month price target is $51.75, suggesting that the stock has a possible downside of 40.81%. The high price target for ENTA is $80.00 and the low price target for ENTA is $36.00. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.252.252.502.75
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $51.75$51.25$45.25$45.25
Price Target Upside: 40.81% downside42.45% downside22.89% downside6.04% downside

Enanta Pharmaceuticals (NASDAQ:ENTA) Consensus Price Target History

Price Target History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ:ENTA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2018Royal Bank of CanadaReiterated RatingHold$80.00LowView Rating Details
2/8/2018JPMorgan ChaseDowngradeOverweight -> NeutralHighView Rating Details
10/4/2017JMP SecuritiesBoost Price Target$40.00 -> $53.00LowView Rating Details
8/8/2017Robert W. BairdBoost Price TargetNeutral$27.00 -> $36.00MediumView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Enanta Pharmaceuticals (NASDAQ:ENTA) Earnings History and Estimates Chart

Earnings by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ:ENTA) Earnings Estimates

Current Year EPS Consensus Estimate: $1.04 EPS
Next Year EPS Consensus Estimate: $-0.85 EPS

Enanta Pharmaceuticals (NASDAQ ENTA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018($0.37)N/AView Earnings Details
2/7/2018Q1 2018$0.05$0.78$27.26 million$38.11 millionViewN/AView Earnings Details
11/20/2017Q4 2017$2.13$1.86$73.80 million$75.93 millionViewN/AView Earnings Details
8/7/2017Q3 2017($0.49)($0.44)$8.08 million$7.51 millionViewListenView Earnings Details
5/8/2017Q2 2017($0.38)($0.28)$9.19 million$9.00 millionViewListenView Earnings Details
2/8/2017Q117($0.18)($0.26)$12.70 million$11.90 millionViewListenView Earnings Details
11/21/2016Q416($0.11)($0.09)$13.56 million$12.80 millionViewListenView Earnings Details
8/8/2016Q216($0.09)($0.06)$13.07 million$14.00 millionViewListenView Earnings Details
5/9/2016Q2$0.10($0.09)$16.80 million$13.00 millionViewListenView Earnings Details
2/8/2016Q116$1.13$1.36$47.32 million$48.40 millionViewListenView Earnings Details
11/23/2015Q415$0.15$0.29$16.44 million$14.40 millionViewListenView Earnings Details
8/6/2015Q315$0.19$0.13$16.18 million$11.60 millionViewListenView Earnings Details
5/7/2015Q215$1.80$1.49$63.40 million$57.40 millionViewListenView Earnings Details
2/5/2015Q115$3.82$2.18$86.62 million$77.50 millionViewN/AView Earnings Details
11/24/2014Q414($0.33)($0.27)$3.81 million$2.60 millionViewListenView Earnings Details
8/11/2014Q314$1.65$1.81$40.83 million$42.10 millionViewN/AView Earnings Details
5/12/2014Q2$0.69($0.28)$1.20 million$2.20 millionViewListenView Earnings Details
2/13/2014Q114($0.15)($0.30)$1.41 million$0.8930 millionViewN/AView Earnings Details
11/25/2013Q4($0.29)($0.25)$1.00 million$1.30 millionViewListenView Earnings Details
8/12/2013Q213($0.34)($0.23)$0.73 million$1.60 millionViewN/AView Earnings Details
5/8/2013Q2 2013$1.45($2.28)$11.00 million$1.20 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Enanta Pharmaceuticals (NASDAQ:ENTA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Enanta Pharmaceuticals (NASDAQ ENTA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.56%
Institutional Ownership Percentage: 73.26%
Insider Trading History for Enanta Pharmaceuticals (NASDAQ:ENTA)
Institutional Ownership by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ ENTA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018Nathalie AddaVPSell4,225$85.58$361,575.5010,225View SEC Filing  
3/19/2018Paul J MellettTreasurerSell9,000$86.48$778,320.0096,458View SEC Filing  
1/4/2017Yat Sun OrInsiderSell13,921$35.09$488,487.89301,876View SEC Filing  
11/29/2016Yat Sun OrInsiderSell13,921$31.44$437,676.24315,797View SEC Filing  
5/11/2016Nathaniel S GardinerVPBuy500$24.45$12,225.001,900View SEC Filing  
2/12/2016Terry VanceDirectorBuy2,000$27.04$54,080.0015,295View SEC Filing  
11/24/2015Paul J. MellettCFOSell6,000$30.15$180,900.0054,397View SEC Filing  
10/15/2015Paul J MellettCFOSell7,500$40.10$300,750.0060,397View SEC Filing  
9/8/2015Paul J. MellettCFOSell7,500$39.55$296,625.0067,897View SEC Filing  
7/13/2015Paul J MellettCFOSell7,500$46.29$347,175.00View SEC Filing  
7/13/2015Yat Sun OrInsiderSell3,750$46.29$173,587.50View SEC Filing  
6/11/2015Paul J MellettCFOSell7,500$42.51$318,825.00View SEC Filing  
6/11/2015Yat Sun OrInsiderSell3,750$42.47$159,262.50View SEC Filing  
6/5/2015Yat Sun OrInsiderSell10,750$42.02$451,715.00View SEC Filing  
5/19/2015Paul J MellettCFOSell24,000$40.13$963,120.00View SEC Filing  
5/11/2015Yat Sun OrInsiderSell8,000$36.13$289,040.00View SEC Filing  
3/9/2015Jay R LulyCEOSell15,000$33.37$500,550.00View SEC Filing  
2/20/2015Jay R LulyCEOSell15,000$35.35$530,250.00View SEC Filing  
2/19/2015Stephen Jr. BuckleyDirectorBuy1,000$34.00$34,000.00View SEC Filing  
2/17/2015Nathaniel S GardinerVPBuy1,400$33.23$46,522.00View SEC Filing  
1/16/2015Paul J MellettCFOSell4,500$49.45$222,525.00View SEC Filing  
1/5/2015Jay R LulyCEOSell15,000$50.43$756,450.00View SEC Filing  
12/1/2014Jay R LulyCEOSell15,000$45.39$680,850.00View SEC Filing  
11/3/2014Jay R LulyCEOSell15,000$42.52$637,800.00View SEC Filing  
9/15/2014Paul J MellettCFOSell10,000$39.83$398,300.00View SEC Filing  
8/14/2014Paul J MellettCFOSell10,000$39.13$391,300.00View SEC Filing  
8/14/2014Stephen Jr. BuckleyDirectorBuy1,000$38.95$38,950.00View SEC Filing  
7/14/2014Paul J MellettCFOSell20,000$39.88$797,600.00View SEC Filing  
5/1/2014Yat Sun OrInsiderSell5,000$36.98$184,900.00184,078View SEC Filing  
4/1/2014Jay LulyCEOSell15,000$39.17$587,550.00544,338View SEC Filing  
4/1/2014Yat Sun OrInsiderSell10,000$39.16$391,600.00189,078View SEC Filing  
3/24/2014Yat Sun OrInsiderSell10,000$39.34$393,400.00199,078View SEC Filing  
3/4/2014V Life Science Ventures Gm Tvmmajor shareholderSell439,334$38.82$17,054,945.88View SEC Filing  
2/26/2014V Life Science Ventures Gm Tvmmajor shareholderSell230,190$39.15$9,011,938.50View SEC Filing  
2/24/2014V Life Science Ventures Gm Tvmmajor shareholderSell60,477$39.57$2,393,074.89View SEC Filing  
2/14/2014Jay LulyCEOSell5,800$38.10$220,980.00569,338View SEC Filing  
1/2/2014Jay R LulyCEOSell5,800$28.05$162,690.00View SEC Filing  
12/6/2013Marc E GoldbergDirectorSell6,861$27.93$191,627.73View SEC Filing  
10/14/2013Saints Capital Granite, L.P.Major ShareholderSell32,301$19.84$640,851.84View SEC Filing  
10/10/2013Saints Capital Granite, L.P.Major ShareholderSell36,207$21.71$786,053.97View SEC Filing  
10/3/2013Saints Capital Granite, L.P.Major ShareholderSell12,300$23.39$287,697.00View SEC Filing  
3/26/2013Helmut SchuhslerDirectorBuy132,949$14.00$1,861,286.00View SEC Filing  
3/26/2013Saints Capital Granite, L.P.Major ShareholderBuy66,474$14.00$930,636.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Enanta Pharmaceuticals (NASDAQ ENTA) News Headlines

Source:
DateHeadline
Enanta Pharmaceuticals (ENTA) VP Nathalie Adda Sells 4,225 SharesEnanta Pharmaceuticals (ENTA) VP Nathalie Adda Sells 4,225 Shares
www.americanbankingnews.com - April 18 at 7:29 PM
Blog Exposure - Enanta Pharma Announced Presentation of New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASHBlog Exposure - Enanta Pharma Announced Presentation of New Data for Core Inhibitor for Hepatitis B Virus and FXR Agonist EDP-305 for NASH
finance.yahoo.com - April 16 at 8:55 AM
$30.01 Million in Sales Expected for Enanta Pharmaceuticals (ENTA) This Quarter$30.01 Million in Sales Expected for Enanta Pharmaceuticals (ENTA) This Quarter
www.americanbankingnews.com - April 13 at 2:21 AM
Robert W. Baird Boosts Enanta Pharmaceuticals (ENTA) Price Target to $36.00Robert W. Baird Boosts Enanta Pharmaceuticals (ENTA) Price Target to $36.00
www.americanbankingnews.com - April 12 at 8:29 PM
Enanta Pharmaceuticals (ENTA) Given Average Recommendation of "Buy" by AnalystsEnanta Pharmaceuticals (ENTA) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 12 at 11:47 AM
Enanta Pharmaceuticals (ENTA) Expected to Post Earnings of $0.10 Per ShareEnanta Pharmaceuticals (ENTA) Expected to Post Earnings of $0.10 Per Share
www.americanbankingnews.com - April 11 at 5:18 PM
Enanta Pharmaceuticals (ENTA) Downgraded by Zacks Investment Research to HoldEnanta Pharmaceuticals (ENTA) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 10 at 11:04 PM
Rigel Pharmaceuticals (RIGL) Soars: Stock Adds 8.2% in SessionRigel Pharmaceuticals (RIGL) Soars: Stock Adds 8.2% in Session
finance.yahoo.com - April 5 at 11:05 AM
Bio-Path Leukemia Combo Study Shows Positive Early DataBio-Path Leukemia Combo Study Shows Positive Early Data
finance.yahoo.com - April 4 at 3:39 PM
Enanta Pharmaceuticals (ENTA) Rating Reiterated by Royal Bank of CanadaEnanta Pharmaceuticals (ENTA) Rating Reiterated by Royal Bank of Canada
www.americanbankingnews.com - April 4 at 11:42 AM
Report: Developing Opportunities within Enanta Pharmaceuticals, ServisFirst Bancshares, Lion Biotechnologies, Peapack-Gladstone Financial, Analogic, and Akcea Therapeutics — Future Expectations, Projections Moving into 2018Report: Developing Opportunities within Enanta Pharmaceuticals, ServisFirst Bancshares, Lion Biotechnologies, Peapack-Gladstone Financial, Analogic, and Akcea Therapeutics — Future Expectations, Projections Moving into 2018
finance.yahoo.com - April 4 at 9:05 AM
Enanta Pharmaceuticals (ENTA) Upgraded to Strong-Buy at ValuEngineEnanta Pharmaceuticals (ENTA) Upgraded to Strong-Buy at ValuEngine
www.americanbankingnews.com - April 3 at 4:16 PM
Enanta Pharmaceuticals (ENTA) Rating Lowered to Sector Perform at Royal Bank of CanadaEnanta Pharmaceuticals (ENTA) Rating Lowered to Sector Perform at Royal Bank of Canada
www.americanbankingnews.com - March 31 at 12:49 PM
Enanta Pharma (ENTA) Announces Data Presentations at The International Liver CongressEnanta Pharma (ENTA) Announces Data Presentations at The International Liver Congress
www.streetinsider.com - March 28 at 4:47 PM
Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress 2018Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress 2018
www.finanznachrichten.de - March 28 at 9:14 AM
Enanta Pharmaceuticals Inc (ENTA) Expected to Announce Quarterly Sales of $30.01 MillionEnanta Pharmaceuticals Inc (ENTA) Expected to Announce Quarterly Sales of $30.01 Million
www.americanbankingnews.com - March 27 at 3:40 AM
Zacks: Analysts Anticipate Enanta Pharmaceuticals Inc (ENTA) Will Announce Earnings of $0.10 Per ShareZacks: Analysts Anticipate Enanta Pharmaceuticals Inc (ENTA) Will Announce Earnings of $0.10 Per Share
www.americanbankingnews.com - March 25 at 7:12 PM
Enanta Pharmaceuticals Inc (ENTA) Treasurer Paul J. Mellett Sells 9,000 SharesEnanta Pharmaceuticals Inc (ENTA) Treasurer Paul J. Mellett Sells 9,000 Shares
www.americanbankingnews.com - March 20 at 7:34 PM
Enanta Pharmaceuticals Inc (ENTA) Given Consensus Rating of "Buy" by BrokeragesEnanta Pharmaceuticals Inc (ENTA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - March 18 at 11:40 AM
Enanta Pharmaceuticals (ENTA) Raised to Strong-Buy at BidaskClubEnanta Pharmaceuticals (ENTA) Raised to Strong-Buy at BidaskClub
www.americanbankingnews.com - March 14 at 7:50 PM
Enanta Pharmaceuticals Inc (ENTA) Expected to Post Quarterly Sales of $30.01 MillionEnanta Pharmaceuticals Inc (ENTA) Expected to Post Quarterly Sales of $30.01 Million
www.americanbankingnews.com - March 10 at 6:06 AM
 Analysts Expect Enanta Pharmaceuticals Inc (ENTA) to Post $0.10 EPS Analysts Expect Enanta Pharmaceuticals Inc (ENTA) to Post $0.10 EPS
www.americanbankingnews.com - March 8 at 1:36 PM
Bristol-Myers' Opdivo gets FDA Nod for Every Four Week DosingBristol-Myers' Opdivo gets FDA Nod for Every Four Week Dosing
finance.yahoo.com - March 8 at 9:13 AM
Annual HC Wainwright NASH Investor Conference - Business Wire (press release)Annual HC Wainwright NASH Investor Conference - Business Wire (press release)
www.businesswire.com - March 7 at 5:43 PM
Dermiras Acne Candidate Fails in Pivotal Trials, Shares SinkDermira's Acne Candidate Fails in Pivotal Trials, Shares Sink
finance.yahoo.com - March 6 at 5:08 PM
Enanta Pharmaceuticals Inc (ENTA) Holdings Reduced by Stonepine Capital Management LLCEnanta Pharmaceuticals Inc (ENTA) Holdings Reduced by Stonepine Capital Management LLC
www.americanbankingnews.com - March 6 at 9:58 AM
Enanta Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright NASH Investor ConferenceEnanta Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright NASH Investor Conference
finance.yahoo.com - March 6 at 8:54 AM
Enanta Pharmaceuticals (ENTA) Stock Rating Upgraded by ValuEngineEnanta Pharmaceuticals (ENTA) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 4 at 7:16 PM
Commit To Buy Enanta Pharmaceuticals At $55, Earn 6% Annualized Using Options - NasdaqCommit To Buy Enanta Pharmaceuticals At $55, Earn 6% Annualized Using Options - Nasdaq
www.nasdaq.com - February 25 at 9:19 AM
Enanta Pharmaceuticals Inc (ENTA) Given Average Rating of "Hold" by AnalystsEnanta Pharmaceuticals Inc (ENTA) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - February 21 at 11:42 AM
AbbVie Presents New Data on Upadacitinib for Crohns DiseaseAbbVie Presents New Data on Upadacitinib for Crohn's Disease
www.msn.com - February 21 at 9:01 AM
 Analysts Anticipate Enanta Pharmaceuticals Inc (ENTA) Will Announce Quarterly Sales of $30.01 Million Analysts Anticipate Enanta Pharmaceuticals Inc (ENTA) Will Announce Quarterly Sales of $30.01 Million
www.americanbankingnews.com - February 21 at 2:58 AM
Enanta Pharmaceuticals Inc (ENTA) Expected to Post Earnings of $0.10 Per ShareEnanta Pharmaceuticals Inc (ENTA) Expected to Post Earnings of $0.10 Per Share
www.americanbankingnews.com - February 19 at 7:20 PM
Enanta Pharmaceuticals (ENTA) Upgraded to Buy at Zacks Investment ResearchEnanta Pharmaceuticals (ENTA) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - February 12 at 11:18 PM
Enanta Pharmaceuticals to Present at Two Upcoming Investor ConferencesEnanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
finance.yahoo.com - February 12 at 9:26 AM
Enanta Pharmaceuticals (ENTA) Rating Lowered to Neutral at JPMorgan Chase & Co.Enanta Pharmaceuticals (ENTA) Rating Lowered to Neutral at JPMorgan Chase & Co.
www.americanbankingnews.com - February 11 at 2:12 PM
Enanta Pharmaceuticals (ENTA) PT Raised to $78.00 at Royal Bank of CanadaEnanta Pharmaceuticals (ENTA) PT Raised to $78.00 at Royal Bank of Canada
www.americanbankingnews.com - February 11 at 1:06 PM
Enanta Pharmaceuticals (ENTA) Lowered to "Buy" at BidaskClubEnanta Pharmaceuticals (ENTA) Lowered to "Buy" at BidaskClub
www.americanbankingnews.com - February 10 at 11:40 AM
Should You Sell Enanta Pharmaceuticals Inc (NASDAQ:ENTA) At This PE Ratio?Should You Sell Enanta Pharmaceuticals Inc (NASDAQ:ENTA) At This PE Ratio?
finance.yahoo.com - February 8 at 4:07 PM
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2017Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2017
finance.yahoo.com - February 8 at 8:38 AM
Enanta Pharmaceuticals posts 1Q profitEnanta Pharmaceuticals posts 1Q profit
finance.yahoo.com - February 8 at 8:38 AM
 Brokerages Expect Enanta Pharmaceuticals Inc (ENTA) to Announce $0.05 EPS Brokerages Expect Enanta Pharmaceuticals Inc (ENTA) to Announce $0.05 EPS
www.americanbankingnews.com - February 2 at 7:10 PM
Enanta Pharmaceuticals (ENTA) Lowered to Sell at Zacks Investment ResearchEnanta Pharmaceuticals (ENTA) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - January 30 at 10:48 PM
Enanta Pharmaceuticals (ENTA) Set to Announce Quarterly Earnings on TuesdayEnanta Pharmaceuticals (ENTA) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - January 30 at 4:08 AM
Enanta Pharmaceuticals Inc (ENTA) Receives Average Rating of "Hold" from AnalystsEnanta Pharmaceuticals Inc (ENTA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - January 27 at 11:56 AM
Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2017Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2017
finance.yahoo.com - January 24 at 9:58 AM
Enanta Pharmaceuticals Inc (ENTA) Expected to Announce Quarterly Sales of $27.26 MillionEnanta Pharmaceuticals Inc (ENTA) Expected to Announce Quarterly Sales of $27.26 Million
www.americanbankingnews.com - January 18 at 2:38 AM
Enanta Pharmaceuticals Inc (ENTA) Expected to Announce Earnings of $0.05 Per ShareEnanta Pharmaceuticals Inc (ENTA) Expected to Announce Earnings of $0.05 Per Share
www.americanbankingnews.com - January 16 at 9:24 PM
Enanta Pharma (ENTA) Provides Updates on R&D Programs and Business Outlook Ahead of JP Morgan Healthcare ... - StreetInsider.comEnanta Pharma (ENTA) Provides Updates on R&D Programs and Business Outlook Ahead of JP Morgan Healthcare ... - StreetInsider.com
www.streetinsider.com - January 7 at 5:32 PM
Enanta Pharma (ENTA) Provides Updates on R&D Programs and Business Outlook Ahead of J.P. Morgan Healthcare ConferenceEnanta Pharma (ENTA) Provides Updates on R&D Programs and Business Outlook Ahead of J.P. Morgan Healthcare Conference
www.streetinsider.com - January 6 at 9:39 AM

SEC Filings

Enanta Pharmaceuticals (NASDAQ:ENTA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Enanta Pharmaceuticals (NASDAQ:ENTA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Enanta Pharmaceuticals (NASDAQ ENTA) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.